Enzolytics, Inc. (ENZC)

OTCMKTS · Delayed Price · Currency is USD
0.0005
0.00 (0.00%)
Mar 9, 2026, 3:51 PM EST
-28.57%
Market Cap 2.42M
Revenue (ttm) 46.59K
Net Income (ttm) -1.03M
Shares Out 4.83B
EPS (ttm) -4.76
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,991,092
Average Volume 7,683,494
Open 0.0005
Previous Close 0.0005
Day's Range 0.0005 - 0.0005
52-Week Range 0.0000 - 0.0011
Beta -0.18
RSI 47.26
Earnings Date n/a

About Enzolytics

Enzolytics Inc., a drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Its patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The company has clinically tested anti-HIV therapeutics. In addition, the company’s proprietary cell line produces human monoclonal antibodies that target and neutralizes the HIV virus. Enzolytics Inc. is b... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Steven Sharabura
Country United States
Stock Exchange OTCMKTS
Ticker Symbol ENZC
Full Company Profile

Financial Performance

In 2011, Enzolytics's revenue was $52,807, an increase of 42.85% compared to the previous year's $36,968. Losses were -$882,928, -88.25% less than in 2010.

Financial Statements

News

There is no news available yet.